or Try an Advanced Search...

    Technical Analysis for IMTX - Immatics N.V.

    Grade Last Price % Change Price Change
    C 12.16 -0.25% -0.03
    IMTX closed down 0.25 percent on Thursday, September 19, 2024, on 56 percent of normal volume.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Flat
    Historical IMTX trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Upper Bollinger Band Walk Strength -0.25%
    Bearish Engulfing Bearish -0.08%
    New Uptrend Bullish -0.08%
    Slingshot Bullish Bullish Swing Setup -0.08%
    Upper Bollinger Band Walk Strength -0.08%
    Overbought Stochastic Strength -0.08%
    Upper Bollinger Band Touch Strength -0.08%
    Pocket Pivot Bullish Swing Setup -4.48%
    Volume Surge Other -4.48%
    Older End-of-Day Signals for IMTX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 2 hours ago
    Possible Inside Day about 3 hours ago
    Fell Below 10 DMA about 3 hours ago
    Reversed from Up about 3 hours ago
    Gap Up Closed about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    IMTX Chart by TradingView
    Basic chart:

    Profile

    Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Treatment Of Cancer Cancer Treatment Cell Therapy Immunotherapies Virotherapy T Cell Adoptive Cell Transfer

    Is IMTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 16 Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
    Sep 6 Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
    Aug 15 Immatics Second Quarter 2024 Earnings: Beats Expectations
    Aug 13 Immatics GAAP EPS of -€0.17, revenue of €18.8M
    Aug 13 Immatics Announces Second Quarter 2024 Financial Results and Business Update
    Jul 31 Immatics Appoints Alise Reicin to Board of Directors
    Jul 25 Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years
    Jul 18 Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
    Jun 14 Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
    May 21 Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
    See more IMTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.77
    52 Week Low 7.1583
    Average Volume 322,357
    200-Day Moving Average 11.41
    50-Day Moving Average 11.83
    20-Day Moving Average 11.68
    10-Day Moving Average 12.19
    Average True Range 0.49
    RSI (14) 55.16
    ADX 26.2
    +DI 25.44
    -DI 12.94
    Chandelier Exit (Long, 3 ATRs) 11.61
    Chandelier Exit (Short, 3 ATRs) 12.35
    Upper Bollinger Bands 12.84
    Lower Bollinger Band 10.51
    Percent B (%b) 0.71
    BandWidth 19.93
    MACD Line 0.20
    MACD Signal Line 0.11
    MACD Histogram 0.089
    Fundamentals Value
    Market Cap 1.25 Billion
    Num Shares 103 Million
    EPS -1.22
    Price-to-Earnings (P/E) Ratio -9.97
    Price-to-Sales 15.41
    Price-to-Book 4.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.78
    Resistance 3 (R3) 12.83 12.67 12.68
    Resistance 2 (R2) 12.67 12.51 12.64 12.64
    Resistance 1 (R1) 12.41 12.41 12.33 12.37 12.61
    Pivot Point 12.25 12.25 12.21 12.23 12.25
    Support 1 (S1) 12.00 12.09 11.92 11.95 11.71
    Support 2 (S2) 11.84 12.00 11.81 11.68
    Support 3 (S3) 11.58 11.84 11.64
    Support 4 (S4) 11.54